John G Nutt

List of Publications by Year
in descending order

101 papers	10,167 citations	43973 48 h-index	38300 95 g-index
102 all docs	102 docs citations	102 times ranked	8278 citing authors

#	Article	IF	Citations
1	Relationship Between Brain Volumes and Objective Balance and Gait Measures in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 283-294.	1.5	5
2	Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease. Movement Disorders, 2022, 37, 264-267.	2.2	10
3	Discussion of Research Priorities for Gait Disorders in Parkinson's Disease. Movement Disorders, 2022, 37, 253-263.	2.2	16
4	Stepping up to meet the challenge of freezing of gait in Parkinsonâ€™s disease. Translational Neurodegeneration, 2022, 11, 23.	3.6	10
5	Reply to: â€œLetter on DiscussionÂof Gait Researchâ€• Movement Disorders, 2022, 37, 1328-1328.	2.2	0
6	Cortical thickness as predictor of response to exercise in people with Parkinson's disease. Human Brain Mapping, 2021, 42, 139-153.	1.9	11
7	Measuring freezing of gait during daily-life: an open-source, wearable sensors approach. Journal of NeuroEngineering and Rehabilitation, 2021, 18, 1.	2.4	131
8	Dual-Task Costs of Quantitative Gait Parameters While Walking and Turning in People with Parkinsonâ€™s Disease: Beyond Gait Speed. Journal of Parkinson's Disease, 2021, 11, 653-664.	1.5	13
9	Changes in prefrontal cortical activity and turning in response to dopaminergic and cholinergic therapy in Parkinson's disease: A randomized cross-over trial. Parkinsonism and Related Disorders, 2021, 86, 10-14.	1.1	8
10	Functional limits of stability and standing balance in people with Parkinsonâ€™s disease with and without freezing of gait using wearable sensors. Gait and Posture, 2021, 87, 123-129.	0.6	9
11	Turning Back the Clock in Parkinsonâ€™s Disease: Practical Recommendations for Managing Diurnal Symptom Worsening. Journal of Parkinson's Disease, 2021, 11, 1471-1473.	1.5	0
12	Relating Response Inhibition, Brain Connectivity, and Freezing of Gait in People with Parkinsonâ€™s Disease. Journal of the International Neuropsychological Society, 2021, 27, 733-743.	1.2	1
13	Responsiveness of Objective vs. Clinical Balance Domain Outcomes for Exercise Intervention in Parkinson's Disease. Frontiers in Neurology, 2020, 11, 940.	1.1	19
14	Laboratory versus daily life gait characteristics in patients with multiple sclerosis, Parkinsonâ€™s disease, and matched controls. Journal of NeuroEngineering and Rehabilitation, 2020, 17, 159.	2.4	38
15	Effects of the agility boot camp with cognitive challenge (ABC-C) exercise program for Parkinsonâ€™s disease. Npj Parkinson's Disease, 2020, 6, 31.	2.5	25
16	Prefrontal Cortex Activity and Gait in Parkinson's Disease With Cholinergic and Dopaminergic Therapy. Movement Disorders, 2020, 35, 2019-2027.	2.2	25
17	Effect of Bout Length on Gait Measures in People with and without Parkinsonâ€™s Disease during Daily Life. Sensors, 2020, 20, 5769.	2.1	23
18	Digital Biomarkers of Mobility in Parkinsonâ€™s Disease During Daily Living. Journal of Parkinson's Disease, 2020, 10, 1099-1111.	1.5	40

#	Article	IF	Citations
19	Aromatic Lâ€Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease. Movement Disorders, 2020, 35, 851-858.	2.2	23
20	Lateralized Connectivity between Globus Pallidus and Motor Cortex is Associated with Freezing of Gait in Parkinsonâ€™s Disease. Neuroscience, 2020, 443, 44-58.	1.1	14
21	Quantity and quality of gait and turning in people with multiple sclerosis, Parkinsonâ€™s disease and matched controls during daily living. Journal of Neurology, 2020, 267, 1188-1196.	1.8	47
22	How to Select Balance Measures Sensitive to Parkinsonâ€™s Disease from Body-Worn Inertial Sensorsâ€”Separating the Trees from the Forest. Sensors, 2019, 19, 3320.	2.1	44
23	Effects of augmenting cholinergic neurotransmission on balance in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 69, 40-47.	1.1	18
24	Magnetic resonance imagingâ€“guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease. Annals of Neurology, 2019, 85, 704-714.	2.8	101
25	Overview of the cholinergic contribution to gait, balance and falls in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 63, 20-30.	1.1	49
26	Apraxia of gait- or apraxia of postural transitions?. Parkinsonism and Related Disorders, 2018, 50, 19-22.	1.1	10
27	Neurological disorders of gait, balance and posture: a sign-based approach. Nature Reviews Neurology, 2018, 14, 183-189.	4.9	88
28	Non-Dopaminergic Therapies. Journal of Parkinson's Disease, 2018, 8, S73-S78.	1.5	7
29	Assessment of the ability of open- and closed-loop cueing to improve turning and freezing in people with Parkinsonâ€™s disease. Scientific Reports, 2018, 8, 12773.	1.6	52
30	Gait Stability Has Phase-Dependent Dual-Task Costs in Parkinsonâ€™s Disease. Frontiers in Neurology, 2018, 9, 373.	1.1	26
31	Dual task interference on postural sway, postural transitions and gait in people with Parkinsonâ€™s disease and freezing of gait. Gait and Posture, 2017, 56, 76-81.	0.6	104
32	The clinical significance of freezing while turning in Parkinsonâ€™s disease. Neuroscience, 2017, 343, 222-228.	1.1	101
33	Investigation of Anticipatory Postural Adjustments during One-Leg Stance Using Inertial Sensors: Evidence from Subjects with Parkinsonism. Frontiers in Neurology, 2017, 8, 361.	1.1	22
34	Recovery from Multiple APAs Delays Gait Initiation in Parkinsonâ€™s Disease. Frontiers in Human Neuroscience, 2017, 11, 60.	1.0	25
35	Impaired perception of surface tilt in progressive supranuclear palsy. PLoS ONE, 2017, 12, e0173351.	1.1	19
36	Motor subtype in Parkinson's disease: Different disorders or different stages of disease?. Movement Disorders, 2016, 31, 957-961.	2.2	86

#	Article	IF	Citations
37	Associations between mobility, cognition and callosal integrity in people with parkinsonism. NeuroImage: Clinical, 2016, 11, 415-422.	1.4	27
38	Balance and Gait Represent Independent Domains of Mobility in Parkinson Disease. Physical Therapy, 2016, 96, 1364-1371.	1.1	77
39	Objective Gait and Balance Impairments Relate to Balance Confidence and Perceived Mobility in People With Parkinson Disease. Physical Therapy, 2016, 96, 1734-1743.	1.1	55
40	Quantifying effects of age on balance and gait with inertial sensors in community-dwelling healthy adults. Experimental Gerontology, 2016, 85, 48-58.	1.2	51
41	Pharmacological treatment in Parkinson's disease: Effects on gait. Parkinsonism and Related Disorders, 2016, 31, 3-13.	1.1	120
42	Continuous monitoring of turning in Parkinsonâ€™s disease: Rehabilitation potential. NeuroRehabilitation, 2015, 37, 3-10.	0.5	135
43	Effect of augmenting cholinergic function on gait and balance. BMC Neurology, 2015, 15, 264.	0.8	23
44	Levodopa <scp>I</scp>s a <scp>D</scp>oubleâ€<scp>E</scp>dged <scp>S</scp>word for <scp>B</scp>alance and <scp>G</scp>ait in <scp>P</scp>eople <scp>W</scp>ith <scp>P</scp>arkinson's <scp>D</scp>isease. Movement Disorders, 2015, 30, 1361-1370.	2.2	300
45	Freezing of gait: a practical approach to management. Lancet Neurology, The, 2015, 14, 768-778.	4.9	276
46	Reply: Does dominant pedunculopontine nucleus exist? Probably not. Brain, 2015, 138, e347-e347.	3.7	0
47	Dual-task interference and brain structural connectivity in people with Parkinson's disease who freeze. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 786-792.	0.9	70
48	Life-sustaining treatment orders, location of death and co-morbid conditions in decedents with Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 1205-1209.	1.1	25
49	Preferences of Patients With Parkinsonâ€™s Disease for Communication About Advanced Care Planning. American Journal of Hospice and Palliative Medicine, 2015, 32, 68-77.	0.8	62
50	Reply: Does dominant pedunculopontine nucleus exist?. Brain, 2015, 138, e324-e324.	3.7	2
51	Cognitive and Motor Function in Long-DurationPARKIN-Associated Parkinson Disease. JAMA Neurology, 2014, 71, 62.	4.5	49
52	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. JAMA Neurology, 2014, 71, 543.	4.5	312
53	Dual tasking during postural stepping responses increases falls but not freezing in people with Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 779-781.	1.1	31
54	Comorbidity and Functional Mobility in Persons with Parkinson Disease. Archives of Physical Medicine and Rehabilitation, 2014, 95, 2152-2157.	0.5	45

#	Article	IF	Citations
55	Inhibition, Executive Function, and Freezing of Gait. Journal of Parkinson's Disease, 2014, 4, 111-122.	1.5	79
56	Functional Reorganization of the Locomotor Network in Parkinson Patients with Freezing of Gait. PLoS ONE, 2014, 9, e100291.	1.1	164
57	Framework for understanding balance dysfunction in Parkinson's disease. Movement Disorders, 2013, 28, 1474-1482.	2.2	172
58	Higherâ€level gait disorders: An open frontier. Movement Disorders, 2013, 28, 1560-1565.	2.2	69
59	Quantifying freezing of gait in Parkinson's disease during the instrumented timed up and go test. , 2012, 2012, 1198-201.		41
60	Freezing of gait: moving forward on a mysterious clinical phenomenon. Lancet Neurology, The, 2011, 10, 734-744.	4.9	1,003
61	Milestones in gait, balance, and falling. Movement Disorders, 2011, 26, 1166-1174.	2.2	75
62	iTUG, a Sensitive and Reliable Measure of Mobility. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2010, 18, 303-310.	2.7	426
63	Dyskinesia and the antiparkinsonian response always temporally coincide. Neurology, 2010, 74, 1191-1197.	1.5	47
64	Preparation for Compensatory Forward Stepping in Parkinson's Disease. Archives of Physical Medicine and Rehabilitation, 2010, 91, 1332-1338.	0.5	63
65	Knee trembling during freezing of gait represents multiple anticipatory postural adjustments. Experimental Neurology, 2009, 215, 334-341.	2.0	217
66	Reply: Continuous stimulation: Is it the answer to the motor complications of levodopa. Movement Disorders, 2008, 23, 1063-1063.	2.2	0
67	Pharmacokinetics and pharmacodynamics of levodopa. Movement Disorders, 2008, 23, S580-S584.	2.2	121
68	Effects of a NR2B selective NMDA glutamate antagonist, CPâ€101,606, on dyskinesia and parkinsonism. Movement Disorders, 2008, 23, 1860-1866.	2.2	126
69	Effects of Methylphenidate on Response to Oral Levodopa. Archives of Neurology, 2007, 64, 319.	4.9	35
70	Diagnosis and Initial Management of Parkinson's Disease. New England Journal of Medicine, 2005, 353, 1021-1027.	13.9	285
71	The dopamine transporter: Importance in Parkinson's disease. Annals of Neurology, 2004, 55, 766-773.	2.8	116
72	Long-term l-DOPA therapy: challenges to our understanding and for the care of people with Parkinson's disease. Experimental Neurology, 2003, 184, 9-13.	2.0	19

#	Article	IF	Citations
73	Gait and balance disorders. , 2002, , 581-592.		3
74	Evolution of the response to levodopa during the first 4 years of therapy. Annals of Neurology, 2002, 51, 686-693.	2.8	108
75	Exacerbated physical fatigue and mental fatigue in Parkinson's disease. Movement Disorders, 2001, 16, 190-196.	2.2	211
76	Determinants of tapping speed in normal control subjects and subjects with Parkinson's disease: Differing effects of brief and continued practice. Movement Disorders, 2000, 15, 843-849.	2.2	70
77	Verbal Fluency Task Affects Gait in Parkinson's Disease with Motor Freezing. Journal of Geriatric Psychiatry and Neurology, 1998, 11, 181-185.	1.2	129
78	Short- and long-duration responses to levodopa during the first year of levodopa therapy. Annals of Neurology, 1997, 42, 349-355.	2.8	99
79	Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypes. Annals of Neurology, 1997, 42, 655-658.	2.8	52
80	Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Movement Disorders, 1997, 12, 285-292.	2.2	99
81	The response to levodopa in parkinson's disease: Imposing pharmacological law and order. Annals of Neurology, 1996, 39, 561-573.	2.8	296
82	Levodopa Reduces Muscle Tone and Lower Extremity Tremor in Parkinsonâ€™s Disease. Canadian Journal of Neurological Sciences, 1995, 22, 280-285.	0.3	48
83	Apomorphine infusional therapy in parkinson's disease: Clinical utility and lack of tolerance. Movement Disorders, 1995, 10, 37-43.	2.2	97
84	Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: Preliminary findings. Movement Disorders, 1995, 10, 329-332.	2.2	84
85	Increased risk of Parkinson's disease in parents and siblings of patients. Annals of Neurology, 1994, 36, 659-661.	2.8	214
86	Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1. Nature Genetics, 1994, 8, 136-140.	9.4	771
87	Does tolerance develop to levodopa? Comparison of 2-and 21-h levodopa infusions. Movement Disorders, 1993, 8, 139-143.	2.2	30
88	Time course of tolerance to apomorphine in parkinsonism. Clinical Pharmacology and Therapeutics, 1992, 52, 504-510.	2.3	39
89	Absorption of apomorphine by various routes in parkinsonism. Movement Disorders, 1991, 6, 212-216.	2.2	71
90	L-Dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys. Annals of Neurology, 1990, 27, 495-499.	2.8	18

#	Article	IF	Citations
91	The short-duration response to apomorphine: Implications for the mechanism of dopaminergic effects in parkinsonism. Annals of Neurology, 1990, 27, 660-665.	2.8	21
92	Letters to the editor. Movement Disorders, 1990, 5, 178-183.	2.2	16
93	Peripheral pharmacokinetics of apomorphine in humans. Annals of Neurology, 1989, 26, 232-238.	2.8	133
94	Duodenal and gastric delivery of levodopa in parkinsonism. Annals of Neurology, 1988, 23, 589-595.	2.8	111
95	Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Movement Disorders, 1988, 3, 188-194.	2.2	509
96	Parkinson's Disease: Evaluation and Therapeutic Strategy. Hospital Practice (1995), 1987, 22, 107-136.	0.5	0
97	On-off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics. Annals of Neurology, 1987, 22, 535-540.	2.8	161
98	Autosomal dominant episodic ataxia: A heterogeneous syndrome. Movement Disorders, 1986, 1, 239-253.	2.2	110
99	The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: The mechanism of action in the treatment of parkinsonism. Annals of Neurology, 1985, 18, 537-543.	2.8	144
100	The â€œOnâ€“Offâ€•Phenomenon in Parkinsonâ€™s Disease. New England Journal of Medicine, 1984, 310, 483-488.	38.9	543
101	Blepharospasm and oromandibular dystonia (Meige's syndrome) in sisters. Annals of Neurology, 1981, 9, 189-191.	2.8	29